GlaxoSmithKline has provided a glimpse at just how much information about the real-world use of drugs is online. In a trawl of Facebook and Twitter, the Big Pharma found 21 million mentions of its products--and the data have already led to the recall of a GSK product.
Researchers at the University of Michigan are trying to speed toward their goal of enrolling 20,000 people in a study by piggybacking onto Facebook's vast social network. And the genotypic and phenotypic data gathering project is off to a brisk start, with more than 2,000 people signing up in the days after its public launch.
Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.
Reuters reports that Facebook is considering setting up patient support communities and has met with people in the medical industry to discuss its plans.
Authorities removed more than 19,000 ads on Facebook, Twitter and YouTube that promoted the illegal sale of medicines.
It is almost four years since Facebook passed 500 million users. And while the role of it and other social media in clinical trials has generated lots of media coverage and conference chatter, the industry is yet to fully embrace the tools. Survey data published this week show just how there is to go.
The FDA has slapped another drugmaker on Facebook. And this time, the agency's complaints don't raise thorny questions or create new gray areas. The untitled letter to Institut Biochimique and its U.S. partner Akrimax Pharmaceuticals is about as garden-variety as they come.
Chatting with the public is not in pharma's comfort zone. Drugmakers are adept at the one-way communication known as direct-to-consumer advertising, and some of them deal well with the media....
Forget a unified theory of social media from the FDA. It's going to be more of a puzzle-piece approach. As Regulatory Focus reports, the FDA plans to issue several more sets of rules for pharma companies using Twitter, Facebook, Pinterest, et al.
Life science vendors face a balancing act when using social media. Giving users the hard sell will bring rejection and reflect badly on the company, but a softly-softly plan might not be noticed at all. Fortunately for vendors, a survey suggests scientists are increasingly accepting of companies on Facebook and Twitter.